A Phase 1/2 interventional study of JCAR017 (lisocabtagene maraleucel) and JCAR017 (lisocabtagene maraleucel) + ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Small Lymphocytic, sponsored by Juno Therapeutics, a Subsidiary of Celgene. Active, not recruiting at 84 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Juno Therapeutics, a Subsidiary of Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb — 1 open to participants now, 3 under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Bristol-Myers Squibb.
Among the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2017, is one of 4 in phase 1/2, and was the 19th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 6 · Phase 3 3
First in 2006; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 320 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 47 across the 21 interventional studies, 209 across the 4 observational. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Juno Therapeutics, a Subsidiary of Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Juno Therapeutics, a Subsidiary of Celgene is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
2 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
| NCT03331198Juno Therapeutics, a Subsidiary of CelgeneStudy Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | 2027-11-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of:
Subjects in the JCAR017 monotherapy cohorts must have received previous treatment as follows:
Subjects in the ibrutinib + JCAR017 combination therapy cohort must either:
Adequate organ function, defined as:
Subjects in venetoclax + JCAR017 combination cohort must:
Exclusion Criteria:
Use of any of the following medications or treatments within the noted time prior to leukapheresis:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)
Biological: JCAR017 (lisocabtagene maraleucel)
Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm + ibrutinib
Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib
Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm
Biological: JCAR017 (lisocabtagene maraleucel)
Subjects will receive venetoclax as bridging anticancer therapy until lymphodepletion chemotherapy/ JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm. After JCAR017 infusion subjects will receive venetoclax until Day 90.
Biological: JCAR017 (lisocabtagene maraleucel) + venetoclax
Subjects will receive JCAR017 monotherapy
Biological: JCAR017 (lisocabtagene maraleucel)
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
Drug page: Lisocabtagene maraleucel
Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
Drug page: Lisocabtagene maraleucel
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
Phase 1 JCAR017 monotherapy arm: adverse events
Proportion of subjects experiencing adverse events
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 monotherapy arm: laboratory abnormalities
Proportion of subjects experiencing laboratory abnormalities
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: adverse events
Proportion of subjects experiencing adverse events
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: laboratory abnormalities
Proportion of subjects experiencing laboratory abnormalities
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm
Proportion of subjects who have CR after treatment with JCAR017 + ibrutinib using iwCLL 2018 guidelines
Time frame: Through post treatment up to Month 48
Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: adverse events
Proportion of subjects experiencing adverse events
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: laboratory abnormalities
Proportion of subjects experiencing laboratory abnormalities
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm
Proportion of subjects who have CR after treatment with JCAR017 + venetoclax using iwCLL 2018 guidelines
Time frame: Through post treatment up to Month 48
Phase 2 JCAR017 monotherapy expansion arm
Proportion of subjects who have CR after treatment with JCAR017 using iwCLL 2018 guidelines
Time frame: Through post treatment up to Month 48
Phase 2 JCAR017 Double exposed monotherapy expansion arm: overall response rate (ORR)
ORR defined as the rate of complete response/remission (CR) \[including complete response/remission with incomplete marrow recovery (Cri)\] plus PR \[including nodular partial response (nPR)\] based on Independent Review Committee (IRC) assessment using International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines
Time frame: Up to approximately 24 months
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: adverse events
Proportion of subjects experiencing adverse events
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: laboratory abnormalities
Proportion of subjects experiencing laboratory abnormalities
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: ORR
Defined as the rate of CR (including CRi)
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: MRD negative response rate in peripheral blood
Proportion of subjects who achieve MRD CR
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: MRD-negative CR rate in peripheral blood
Proportion of subjects who achieve MRD CR
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Duration of response (DOR)
Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Duration of complete response (DoCR)
Defined as the time from first CR or CRi to the earlier date of PD or death due to any cause
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Time to response (TTR)
Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Time to complete response (TTCR)
Defined as the interval from JCAR017 infusion to the first documentation of CR
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: PFS
Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: OS
Defined as the time from JCAR017 infusion to the date of death due to any cause
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: adverse events
Proportion of subject experiencing adverse events
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: lab abnormalities
Proportion of subjects experiencing laboratory abnormalities
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: ORR
Defined as the rate of CR (including CRi)
Time frame: Through post treatment Day 90
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: MRD-negative response rate in peripheral blood
Proportion of subjects who achieve MRD CR
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: MRD-negative CR rate in peripheral blood
Proportion of subjects who achieve MRD CR
Time frame: Through post treatment Day 90
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Duration of response (DOR)
Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Duration of complete response (DoCR)
Defined as the time from first CR or CRi to the earlier date of PD or death due to any cause
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Time to response (TTR)
Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Time to complete response (TTCR)
Defined as the interval from JCAR017 infusion to the first documentation of CR
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: PFS
Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause
Time frame: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: OS
Defined as the time from JCAR017 infusion to the date of death due to any cause
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: adverse events
Proportion of subjects experiencing adverse events
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: laboratory abnormalities
Proportion of subjects experiencing laboratory abnormalities
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: ORR
Defined as the rate of CR (including CRi)
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: MRD negative response rate in peripheral blood
Proportion of subjects who achieve MRD CR
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: MRD-negative CR rate in peripheral blood
Proportion of subjects who achieve MRD CR
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: Duration of response (DOR)
Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: Duration of complete response (DoCR)
Defined as the time from first CR or CRi to the earlier date of PD or death due to any cause
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: Time to response (TTR)
Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: Time to complete response (TTCR)
Defined as the interval from JCAR017 infusion to the first documentation of CR
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: PFS
Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: OS
Defined as the time from JCAR017 infusion to the date of death due to any cause
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: Health-related quality of life (HRQoL) questionnaire
Change from baseline in HRQoL assessed using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: HRQoL questionnaire
Change from baseline in HRQoL assessed using the EORTC chronic lymphocytic leukemia (CLL)-specific module QLQ-CLL-17
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: Health economics and outcomes research (HEOR) questionnaire
Change from baseline in measurement of health utility values using EuroQol instrument EQ-5D-5L
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: HEOR questionnaire
Proportion of participants with intensive care unit (ICU) inpatient days
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Monotherapy Expansion Arm: HEOR questionnaire
Proportion of participants with non-ICU inpatient days
Time frame: Up to 48 months post treatment
Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: adverse events
Proportion of subjects experiencing adverse events
Time frame: Up to approximately 24 months
Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: laboratory abnormalities
Proportion of subjects experiencing laboratory abnormalities
Time frame: Up to approximately 24 months
Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Duration of response (DOR)
Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause
Time frame: Up to approximately 24 months
Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: CR rate
Defined as the rate of CR (including CRi) based on IRC assessment using iwCLL 2018 guidelines
Time frame: Up to approximately 24 months
Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: MRD-negative response rate in peripheral blood
Proportion of subjects who achieve MRD negative status
Time frame: Up to approximately 24 months
Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: MRD-negative CR rate in peripheral blood
Proportion of subjects who achieve MRD-negative CR
Time frame: Up to approximately 24 months
Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Time to response (TTR)
Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR
Time frame: Up to approximately 24 months
Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Time to complete response (TTCR)
Define as the interval from JCAR017 infusion to the first documentation of CR
Time frame: Up to approximately 24 months
Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Progression free survival (PFS)
Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause
Time frame: Up to approximately 24 months
Phase 2 JCAR017 Double-Exposed Monotherapy Expansion Arm: Overall Survival (OS)
Defined as the time from JCAR017 infusion to the date of death due to any cause
Time frame: Up to approximately 24 months
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Nov 2017 (actual). Primary completion is estimated for Nov 2027, 119 months after the start.
Of 50 industry-sponsored phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 104. This study's planned 119 months is above that.
Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisocabtagene maraleucel
Leukemia, Lymphocytic, Chronic, B-Cell →
Juno Therapeutics, a Subsidiary of Celgene →